# Diabetes Research Hub — Monitor Report
**Run date:** 2026-08-08 (automated review run)
**Reviewer:** Hub monitor (read-only; no source files modified)

---

## TL;DR — What's Actionable

**The collection pipeline is still down — this is now a confirmed outage, not staleness.** Every "latest" data file is frozen at **2026-07-17 (22 days ago)**. This is the *second consecutive* daily report to flag it (see `monitor_report_2026-08-07.md`), and no scripts have re-run in the intervening 24 hours. The problem is no longer "data is getting old" — the collection job has stopped and needs **manual attention**. [Certain — verified: no `clinical_trials_snapshot_*` or `pubmed_recent_snapshot_*` file exists after 2026-07-17.]

Nothing in the underlying data changed since yesterday's report. The one new external item worth carrying forward: **retatrutide's full TRIUMPH-2/TRIUMPH-3 Phase 3 readout (announced 2026-07-23)** landed *inside the outage window* and is not in your trial or PubMed snapshots.

**Do this first:** re-run the three baseline scripts. If they fail on execution (not just "no new data"), the cron/scheduler for the collectors is the real problem.

---

## File System Status

| File | Last modified | Age | Status |
|------|--------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 22 d | ⚠️ STALE (>14 d) |
| `pubmed_recent_latest.json` | 2026-07-17 | 22 d | ⚠️ STALE (>14 d) |
| `hub_monitor_report.md` | 2026-07-17 | 22 d | ⚠️ STALE (>14 d) |
| `literature_gap_data.json` | 2026-07-18 | 21 d | ⚠️ STALE (>14 d) |
| `literature_gap_report.md` | 2026-08-07 | 1 d | Fresh file — but re-analyzes frozen 2026-07-17 PubMed data |
| `agent_state.json` | 2026-08-07 | 1 d | Current |

**Evidence — how I know:**
- Dated snapshots run continuously **2026-03-15 → 2026-07-17, then stop.** A directory scan for any snapshot dated after 2026-07-17 returns nothing. [Certain]
- Internal timestamps confirm the freeze, not just filesystem dates: `clinical_trials_latest.json` metadata `generated: 2026-07-17T02:05:53`; `pubmed_recent_latest.json` `generated: 2026-07-17T02:06:39`; `literature_gap_data.json` `generated: 2026-07-17T10:14:41`. [Certain]
- `literature_gap_report.md` carries a fresh 2026-08-07 timestamp but its own header still reads *"Date range: 2020/01/01 to 2026/07/17"* — it re-ran on cached data and produced identical gap rankings. Its freshness is cosmetic. [Certain]

**Root cause [Likely]:** `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py` have not executed since 2026-07-17; `hub_monitor.py` likewise. Only the gap script re-ran (against cache). A 22-day gap with a previously daily cadence points to a failed/disabled scheduler rather than a quiet news period.

---

## Clinical Trial Changes

**No new snapshot since 2026-07-17, so there is nothing new to diff.** The figures below are the frozen state, carried for reference only.

**Totals (frozen 2026-07-17):** 858 trials tracked. Categories: T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 76 · T2D Novel Therapies (Ph2–3) 147 · Devices 236 · Recently Completed w/ Results 321. [Certain — read from metadata block]

**Phase 3 trials to re-check the moment the collector runs** (statuses below are 22 days old and several are contradicted by the news items further down):
- **Vertex** `NCT06832410` / `NCT04786262` — VX-880 (zimislecel) islet cell therapy, T1D
- **Eli Lilly** `NCT07222137` / `NCT07222332` — baricitinib, Stage 3 T1D beta-cell preservation
- **Sanofi** `NCT07088068` — teplizumab vs placebo *(FDA already expanded teplizumab's pediatric label on 2026-06-12 — confirm this trial's status)*
- **Novo Nordisk** `NCT07564414` — CagriSema dosing; `NCT07076199` — insulin icodec
- **Eli Lilly** retatrutide `NCT05929079` / `NCT06260722` / `NCT06297603` — *still marked ACTIVE_NOT_RECRUITING in frozen data despite the 2026-07-23 TRIUMPH readout*
- **AstraZeneca** `NCT07662044/135/213` — elecoglipron oral-incretin Phase 3 cluster

No newly posted results can appear until the collector re-runs.

---

## PubMed Highlights

**Frozen 2026-07-17:** 158 unique papers, 30-day lookback, 16 domains queried, 8 therapies tracked. [Certain — read from metadata]

Because the corpus has not advanced, the cross-domain and tracked-therapy findings are identical to yesterday's report. Highest-value cross-domain papers still on the list: `[42459945]` algorithmic-discrimination risk in pediatric T1D (AI/ML × Closed-Loop × Health Equity, triple-domain) and `[42419792]` comparative obesity-drug effects (orforglipron × retatrutide × CagriSema).

**Known data-quality issue (unchanged):** `domain_results` per-domain counts render as 0 in the file; the real domain tags live inside `papers[]`. Verify this field once the collector re-runs — do not trust per-domain volume until then.

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (re-run 2026-08-07 on 2026-07-17 data). **Validation level: BRONZE** — single analytical source, expert confirmation required per Research Doctrine.

**Top 5 under-researched intersections (Gap Score 100.0, zero joint publications):**
1. **Treg / CAR-T × Neuropathy** — immune-mediated neuropathy as a Treg-modulation target
2. **Beta Cell Regen × Health Equity** — no access analysis of emerging cell therapies
3. **Treg / CAR-T × Health Equity** — no equity analysis of CAR-Treg/TCR-Treg access
4. **Glucokinase × Health Equity** — no equity analysis for the glucokinase-activator drug class
5. **Gene Therapy × LADA** — autoimmune LADA as a gene-therapy candidate, no crossover work
*(6. Drug Repurposing × Health Equity; 7. Insulin Resistance × Islet Transplant, Gap 91.9)*

**Alignment with Tier 1 contribution areas (RESEARCH_DOCTRINE):**
- Gap **#6 Drug Repurposing × Health Equity** sits at the intersection of **Tier 1 #4 (Drug Repurposing Computational Screening, 18/20)** and **Tier 1 #6 (Epidemiological / Health Equity, 17/20)** — the strongest doctrine-aligned target in the list.
- Gap **#2 Beta Cell Regen × Health Equity** also draws on Tier 1 #6.
- The gap analysis itself is **Tier 1 #2 (Literature Synthesis & Gap Analysis, 19/20)** — but running it on 22-day-old literature undercuts its value. Re-run after the PubMed refresh.

Every Gap-100 pair carries the standard caveat: zero joint pubs may be genuine white space *or* a terminology artifact. Verify with a combined-term PubMed search before treating any as a real opportunity.

---

## Breaking News (web check, 2026-08-01 → 08-08)

The strict 7-day window is quiet — no FDA diabetes action or major readout dated within it. [Likely — based on WebSearch; a collector re-run is the authoritative check.]

**Carried forward — material items still absent from your (frozen) data:**
- **Retatrutide TRIUMPH-2 & TRIUMPH-3 full Phase 3 readout — announced 2026-07-23** (16 days ago, inside the outage gap). TRIUMPH-2 (1,152 pts, obesity + T2D): up to **20.8% weight loss, −1.6 pp HbA1c** at 80 wks. TRIUMPH-3 (1,949 pts, obesity + established CVD): up to **22.6% weight loss**. Lilly BLA now expected **Q1 2027**. Your retatrutide Phase 3 trials still read ACTIVE_NOT_RECRUITING. [Significant]
- **Teplizumab (Tzield) — pediatric Stage 3 T1D indication, FDA 2026-06-12.** Relevant to Sanofi `NCT07088068`. [Significant — from prior report, still not in data]
- **Orforglipron (Foundayo) — FDA approval 2026-04-01** (oral GLP-1). [Significant — still not in data]
- **Garzulys (insulin aspart-fsan biosimilar) — FDA approval 2026-07-30.** [Moderate]

*Note:* an "oral Wegovy / oral semaglutide" approval surfaced in search but appears to predate this window (pharmacy availability cited as early 2026); treating it as **not new**. [Guessing on exact date — verify if it matters.]

None of these are reflected in `clinical_trials_latest.json`. A collector re-run should reconcile trial statuses and pull any newly posted results.

---

## Recommended Actions

**Do first — the pipeline is the blocker (everything downstream is unreliable until fixed):**
1. `python baseline_clinical_trials.py` — trials 22 d stale.
2. `python baseline_pubmed_alerts.py` — PubMed 22 d stale.
3. `python hub_monitor.py` — regenerate the file-change baseline (last real run 2026-07-17).
4. Re-run `python project1_literature_gap_analysis.py` **after** step 2, so gap scores reflect current literature.
5. **If steps 1–3 error rather than simply finding no new data, the collectors' scheduler has failed — investigate the cron/scheduled job itself.** Two consecutive daily monitor runs have now flagged the same freeze; auto-recovery is not happening.

**Then reconcile against the tracker (once collectors succeed):**
6. Confirm retatrutide Phase 3 trial statuses/results updated post-2026-07-23 TRIUMPH readout; log in `Diabetes_Research_Tracker.xlsx`.
7. Confirm teplizumab pediatric indication and orforglipron approval are reflected in trial statuses.
8. Watch the AstraZeneca elecoglipron Phase 3 cluster (`NCT07662044/135/213`).

**Analysis (once data is fresh):**
9. Prioritize **Drug Repurposing × Health Equity** — both a Gap-100 intersection and the intersection of Tier 1 #4 and #6.
10. Fix the `domain_results` zero-count field in the PubMed collector.

---

## Data Integrity Notes (per Research Doctrine)
- All gap classifications remain **BRONZE** (single-source; expert validation pending).
- Breaking-news items are from web search and **not yet verified against primary trial records** — treat as leads until the collector confirms.
- No source files were modified in this review run.
- **Escalation:** the collection outage has now persisted across two automated review cycles. If the next run still shows 2026-07-17 data, the collectors require hands-on debugging, not another report.

---
*Automated monitor review — 2026-08-08. Read-only.*
